5 results on '"Quezada Meza, Camila Paz"'
Search Results
2. Phosphorylation of FAM134C by CK2 controls starvation-induced ER-phagy
- Author
-
Di Lorenzo, Giorgia, Iavarone, Francescopaolo, Maddaluno, Marianna, Plata-Gómez, Ana Belén, Aureli, Simone, Quezada Meza, Camila Paz, Cinque, Laura, Palma, Alessandro, Reggio, Alessio, Cirillo, Carmine, Sacco, Francesca, Stolz, Alexandra, Napolitano, Gennaro, Marin, Oriano, Pinna, Lorenzo A, Ruzzene, Maria, Limongelli, Vittorio, Efeyan, Alejo, Grumati, Paolo, Settembre, Carmine, Pinna, Lorenzo A., European Research Council, Italian Association for Cancer Research, Swiss National Supercomputing Center (CSCS), Deutsche Forschungsgemeinschaft (Alemania), Ministerio de Ciencia, Innovación y Universidades (España), Di Lorenzo, Giorgia, Iavarone, Francescopaolo, Maddaluno, Marianna, Plata-Gómez, Ana Belén, Aureli, Simone, Quezada Meza, Camila Paz, Cinque, Laura, Palma, Alessandro, Reggio, Alessio, Cirillo, Carmine, Sacco, Francesca, Stolz, Alexandra, Napolitano, Gennaro, Marin, Oriano, Pinna, Lorenzo A, Ruzzene, Maria, Limongelli, Vittorio, Efeyan, Alejo, Grumati, Paolo, and Settembre, Carmine
- Subjects
Cell death ,Mammals ,Binding affinities ,Multidisciplinary ,Settore BIO/18 ,Autophagosome ,Binding energy ,Chemical activation ,Proteins ,Activation mechanisms ,Autophagy ,Casein kinase 2 ,Endoplasmic reticulum ,Feed conditions ,Non-redundant ,Selective degradation ,Structural similarity - Abstract
Selective degradation of the endoplasmic reticulum (ER) via autophagy (ER-phagy) is initiated by ER-phagy receptors, which facilitate the incorporation of ER fragments into autophagosomes. FAM134 reticulon family proteins (FAM134A, FAM134B, and FAM134C) are ER-phagy receptors with structural similarities and nonredundant functions. Whether they respond differentially to the stimulation of ER-phagy is unknown. Here, we describe an activation mechanism unique to FAM134C during starvation. In fed conditions, FAM134C is phosphorylated by casein kinase 2 (CK2) at critical residues flanking the LIR domain. Phosphorylation of these residues negatively affects binding affinity to the autophagy proteins LC3. During starvation, mTORC1 inhibition limits FAM134C phosphorylation by CK2, hence promoting receptor activation and ER-phagy. Using a novel tool to study ER-phagy in vivo and FAM134C knockout mice, we demonstrated the physiological relevance of FAM134C phosphorylation during starvation-induced ER-phagy in liver lipid metabolism. These data provide a mechanistic insight into ER-phagy regulation and an example of autophagy selectivity during starvation. We thank G. Diez Roux and P. Ashley-Norman for critical reading of the manuscript. We thank the microscopy, MS, advanced histopathology, and FACS facilities at TIGEM Institute. We thank E. Nusco for helping us with AAV injections. Funding: This work was supported by European Research Council (ERC) (714551), Telethon intramural grants, and Associazione Italiana per la Ricerca sul Cancro (AIRC) (IG 2015 Id 17717) (to C.S.) and Telethon Foundation (TMPGCBX16TT), AFM Telethon (Trampoline Grant), and AIRC (MFAG-2020-24856) (to P.G.). G.D.L. is a recipient of AIRC fellowship “Francesco Alicino” (25407). V.L. acknowledges funding from the ERC (101001784), the Italian MIUR-PRIN 2017 (2017FJZZRC), and the Swiss National Supercomputing Center (CSCS) (project ID u8). The work of A.S. was supported by the German Research Foundation DFG (SFB1177/2 and WO210/20-2) and the Dr. Rolf M. Schwiete Stiftung (13/2017). A.E. is supported by the RETOS projects Programme of Spanish Ministry of Science, Innovation and Universities, Spanish State Research Agency (grants SAF2015-67538-R and PID2019-104012RB-I00), and the ERC (638891). A.B.P.-G. is a recipient of Ph.D. fellowship from MICIU/AEI (BES-2017-081381). A.R. is a recipient of Umberto Veronesi Foundation postdoctoral fellowship. Author contributions: G.D.L. and F.I. performed most of the experiments. F.I. and A.B.P.-G. performed in vivo experiments. M.M. performed mutagenesis experiments. S.A. and V.L. performed LC3-FAM134C binding analysis. C.P.Q.M. performed in vitro phosphorylation assays. L.C. analyzed CK2 substrate phosphorylation. F.S., A.P., C.C., and A.S. analyzed proteomic data. G.N. provided critical suggestions. A.R. performed proteomic experiments. A.E. supervised in vivo experiments. M.R., L.A.P., and O.M. supervised CK2 experiments. C.S. designed the study. P.G. and C.S. conceived and supervised the experiments. C.S., P.G., V.L., and M.R. wrote the paper. G.D.L. and F.I. prepared the figures. All the authors read the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Sí
- Published
- 2022
3. Protein Kinase CK2 and SARS-CoV-2: An Expected Interplay Story.
- Author
-
Quezada Meza, Camila Paz and Ruzzene, Maria
- Subjects
- *
PROTEIN kinase CK2 , *COVID-19 pandemic , *SARS-CoV-2 , *COVID-19 , *VIRAL proteins , *KINASES , *SERS spectroscopy - Abstract
Protein kinase CK2 is a Ser/Thr protein kinase that phosphorylates hundreds of substrates mainly related to survival and proliferation pathways. It has long been considered an anti-cancer drug target. However, during the recent COVID-19 pandemic, CK2 inhibitors have been repurposed as anti-SARS-CoV-2 drugs. This was based on the initial finding of CK2 among the proteins of the host cell that interact with the viral proteins and modulate the infection. Since then, several studies have deepened our understanding of the CK2/COVID-19 connection, and we deem it is time to review all the findings. Interestingly, other coronaviruses cross-talk with CK2 as well, with similarities and differences compared to the SARS-CoV-2 case. Therefore, we believe that the analysis of the effects obtained by targeting CK2 in case of coronavirus infections, both at the molecular and phenomenological level, will help in extrapolating information that could be useful not only for COVID-19 (whose pandemic emergency is hopefully turning off) but also for other infections. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Contribution of the CK2 Catalytic Isoforms α and α’ to the Glycolytic Phenotype of Tumor Cells
- Author
-
Zonta, Francesca, primary, Borgo, Christian, additional, Quezada Meza, Camila Paz, additional, Masgras, Ionica, additional, Rasola, Andrea, additional, Salvi, Mauro, additional, Pinna, Lorenzo A., additional, and Ruzzene, Maria, additional
- Published
- 2021
- Full Text
- View/download PDF
5. Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation.
- Author
-
Quezada Meza CP, Salizzato V, Calistri E, Basso M, Zavatti M, Marmiroli S, Salvi M, Carter BZ, Donella-Deana A, Borgo C, and Ruzzene M
- Abstract
Chronic myeloid leukemia (CML) is characterized by the fusion protein BCR::ABL1, a constitutively active tyrosine kinase. The frontline treatment, represented by tyrosine kinase inhibitors (TKIs), has dramatically improved the clinical outcomes of patients. However, TKI resistance through various mechanisms has been reported. In particular, the BCR::ABL11 T315I mutation is associated with resistance to first- and second-generation TKIs and poor survival outcomes. For patients harboring this mutation, treatments with third generation TKIs are indicated, which are however accompanied by adverse events. Protein kinase CK2 is implicated in several human diseases. Although its role in CML has already been proven, its essentialness in T315I-mediated TKI resistance has yet to be investigated. Here we show that CK2 contributes to the aberrantly high signaling pathways in T315I-cells, and that its pharmacological or genetic targeting diminishes those signals, induces apoptosis, and reduces the proliferation and clonogenic potential of T315I-cells. The effects of CK2 inhibition are also observed in the presence of bone marrow stromal cells and under hypoxic conditions, and, remarkably, in patient-derived cells. Moreover, CK2 inhibition or genetic ablation of the CK2α catalytic subunit sensitizes T315I-cells towards TKIs. Collectively, our results suggest the potential benefit of inhibiting CK2 in CML characterized by T315I-dependent resistance., Competing Interests: Declaration of competing interest The authors have nothing to declare., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.